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Human CD4 +  αβ T cells are activated via T-cell receptor recognition of peptide epitopes 
presented by major histocompatibility complex (mHC) class II (mHC-II). The open ends of the 
mHC-II binding groove allow peptide epitopes to extend beyond a central nonamer core region 
at both the amino- and carboxy-terminus. We have previously found that these non-bound   
C-terminal residues can alter T cell activation in an mHC allele-transcending fashion, although 
the  mechanism  for  this  effect  remained  unclear.  Here  we  show  that  modification  of  the   
C-terminal peptide-flanking region of an influenza hemagglutinin (HA305 − 320) epitope can alter 
T-cell receptor binding affinity, T-cell activation and repertoire selection of influenza-specific 
CD4 +  T cells expanded from peripheral blood. These data provide the first demonstration that 
changes in the C-terminus of the peptide-flanking region can substantially alter T-cell receptor 
binding affinity, and indicate a mechanism through which peptide flanking residues could 
influence repertoire selection. 
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D
efence against invading pathogens is the primary function 
of the immune system. To this end, jawed vertebrates have 
evolved an elaborate recombinatorial system to generate 
a hugely diverse range of cell surface-expressed antigen receptors 
that enable the selection and expansion of pathogen-specific cell 
populations  in  response  to  infection.  Heterodimeric  αβ  T-cell 
receptor  (TCR)  binding  to  cognate  peptide-major  histocompat-
ibility complex (pMHC) antigen underpins the effective activation 
of specific T-cell populations1. These primary recognition events 
occur in the context of a naïve T-cell pool that comprises ~25×106 
distinct TCR clonotypes2.
TCR diversity is generated during the somatic rearrangement of 
T receptor (TR) genes and is driven mechanistically by the imprecise 
stochastic recombination of variable (V), diversity (D) and joining 
(J) gene segments, exonucleolytic activity, random non-templated 
nucleotide  additions  and  differential  chain  pairing.  The  highly 
variable complementarity-determining region 3 (CDR3) is formed 
by the resulting VDJ segment for TCRβ chains; an analogous VJ 
recombination  process  generates  CDR3α  (ref.  3).  Multiple  TCR 
clonotypes can respond to an antigenic stimulus, and measurement 
of either CDR3β lengths or sequences within defined T-cell popula-
tions can provide an indication of repertoire size and variability4,5.
CD4 +  T cells recognize antigens presented by classical MHC-II 
molecules. Limited structural studies of TCR binding to pMHC-II 
have demonstrated that the CDR3 loops contact exposed residues in 
the epitope backbone and engender TCR specificity6. This docking 
strategy is akin to that observed within the more extensive structural 
dataset available for TCR binding to pMHC-I (ref. 6). In humans, the 
most frequent MHC-II presenting element is the human leukocyte 
antigen (HLA)-DR αβ heterodimer. The HLA-DR α-chain is mon-
omorphic, whereas the β-chain is highly polymorphic and generates 
a binding motif for selected peptide epitopes7,8. The core epitope is a 
nonamer peptide bound through a series of pockets in the HLA-DR 
heterodimer at position (P)1, P4, P6 and P9. However, the binding 
groove of the HLA-DR heterodimer is open at either end, which 
allows longer peptides to bind with the non-bound flanking regions 
extending from the amino-terminus (for example, P − 1, P − 2) and 
carboxy-terminus (for example, P10, P11) of the peptide9. We have 
previously eluted and sequenced multiple ligands from a range of 
MHC-II molecules and identified not only core MHC-specific bind-
ing motifs, but also enrichment in the non-bound flanking residues, 
particularly basic residues at the C-terminus; this latter observa-
tion  is  allele-transcending10,11.  Furthermore,  it  has  been  shown 
that residue alteration in the flanking regions of peptides can alter 
their immunogenicity, although the mechanism that underpins this 
observation is unknown11–15.
Biophysical investigations of the TCR/pMHC interaction show 
that TCRs bind very weakly, compared for instance to antibodies, 
with equilibrium binding constants (KDs) usually in the region of 
~10–100 µM; the strength and/or duration of the TCR/pMHC inter-
action are probably the chief parameters that govern T-cell activa-
tion16,17. By studying multiple TCR/pMHC interactions, we have 
found that pMHC-I-restricted TCRs bind with markedly stronger 
affinities (mean KD = 13 µM) compared with pMHC-II-restricted 
TCRs  (mean  KD = 52 µM)18.  Although  it  is  clear  that  there  is  a 
natural range of affinities within which a TCR functions, we have 
also found that the progression from agonist to weak agonist to 
antagonist peptide ligands reflects a steady decline in TCR/pMHC 
affinity19. Conversely, although augmented T-cell effector function 
might follow an increase in TCR/pMHC affinity, very high affinity 
interactions raise the possibility of cross-reactivity at the expense 
of specificity.
The generation of effective CD4 +  T-cell responses is critically 
important for protective immunity, both during infection and fol-
lowing vaccination. Indeed, even a transient failure of the CD4 +  
T-cell  response  may  offer  a  window  for  pathogen  persistence20. 
Primary  T-cell  responses  are  frequently  broad  and  include  low-
avidity clonotypes owing to the efficiency of cognate naïve T-cell 
recruitment21, but the evolution of an effective T-cell response can 
involve preferential selection for fewer clonotypes with higher avid-
ity interactions22–24. Strategies that augment or select a repertoire 
that comprises clonotypes with higher affinity TCRs may therefore 
be attractive from an interventional perspective, especially if this 
can be implemented without sacrificing antigen specificity. In this 
regard, substitutions of amino acids in the core epitope may be risky, 
because they can both alter TCR specificity and unpredictably affect 
TCR binding strength and subsequent T-cell activation25,26.
Here we examine how substitutions in the non-core C-terminal   
flanking  region  of  the  well-characterized  universal  influenza 
hemagglutinin (HA305 − 320) epitope27 affect T-cell recognition and 
TCR selection. Multiple different amino-acid substitutions of resi-
dues in the C-terminus at P10 and P11 were tested against cognate 
T-cell clones. The effects of favourable substitutions on recognition 
by polyclonal cognate T cells derived from the memory pool were 
then explored, and biophysical analyses of TCR/pMHC-II binding 
were conducted using surface plasmon resonance (SPR) to pro-
vide molecular insight into these effects. These data provide the 
first demonstration that modifications to the C-terminal peptide- 
flanking region can directly alter TCR binding affinity and T-cell 
repertoire selection.
Results
Flu-specific CD4 +  T cells prefer C-terminal basic residues. Three 
CD4 +  T-cell clones (HA-C6, HA-C5 and HA-CA), each specific 
for  HLA-DR1/HA305 − 320  (Flu1),  were  screened  using  IFN-γ 
ELISpot assays for recognition of peptides with a conserved core 
epitope  (HA309 − 317)  but  variant  C-terminal  flanking  regions  at 
either P10 (HA318) or P11 (HA319). A total of 22 different 16mer 
peptide variants of HA305 − 320, listed in the Methods, were tested in 
these assays. Representative data generated with the HA-CA clone 
are shown in Figure 1a. The most favoured to the least favoured 
substitutions were ranked for each clone (Fig. 1b), demonstrating 
a  preference  for  positively  charged  basic  residues  (Lys,  Arg)  at 
P10  and  P11.  Indeed,  a  comparison  across  all  three  clones  of 
basic/acidic residues versus all other amino acids in the top three 
recognition positions (Fig. 1b) revealed a significant enrichment of 
positively charged over negatively charged residues (Fisher’s exact 
test P = 0.0045). This striking reluctance to accept acidic residues is 
illustrated in the screening data generated with clone HA-CA, which 
showed reduced activation with Asp or Glu at either P10 or P11 
(Fig. 1a). Although this particular clone did not favour Arg at P10, 
other clones showed a striking increase in responsiveness to altered 
peptides with an Arg at either P10 (Flu2) or P11 (Flu3) (Fig. 1c).
CD4 +  T-cell clonotypic responses to modified Flu-epitopes. Pep-
tides modified in their non-core bound C-terminal flanking region 
seemed  to  alter  the  degree  of  T-cell  activation.  To  examine  this 
observation further, we used modified peptides to expand CD4 +  T 
cells from the influenza-specific memory pool of two HLA-DR1 +  
donors (known responders to HA305 − 320). Ten-day cultures of 106 
peripheral blood mononuclear cells (PBMCs) with the peptides Flu1 
(wild-type sequence) or Flu2 (Arg at P10) expanded ≥5×104 CD4 +  
HLA-DR1/HA305 − 320 tetramer-positive cells (data not shown). We 
investigated TCR usage by these amplified populations (Flu1 ver-
sus Flu2) to establish whether different repertoires were deployed 
against peptide epitopes with C-terminal modifications. Initially, we 
employed TCR spectratyping on HLA-DR1/HA305 − 320 tetramer-
sorted cells, comparing the immunoscope profiles of each T-cell 
receptor beta variable (TRBV) family the relative representation of 
each TRBV family in background peripheral blood, CD4 +  T-cell 
lines expanded with the wild-type Flu1 peptide and, CD4 +  T-cell 
lines expanded with the basic tail Flu2 peptide (Fig. 2).ARTICLE     
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The baseline range and polyclonality of the TCR repertoire was 
demonstrated in peripheral blood using specific primers to amplify 
each TRBV family and by analysing CDR3β length profiles within 
each TRBV family; for the latter, the expected Gaussian distribu-
tion  pattern  was  observed  (Supplementary  Fig.  S1).  Expansion 
of antigen-specific CD4 +  T cells by peptide stimulation (Flu1 or   
Flu2) was reflected by distinct peaks in the immunoscope profiles, 
corresponding  to  individual  T-cell  clonotypes.  The  introduction 
of a C-terminal Arg at P10 in Flu2 led to both skewing of TRBV 
family usage and altered TCR representation within the expanded 
TRBV families (Fig. 2). This experiment was repeated with another 
HLA-DR1 +  donor; similar selective expansions within the CD4 +  
T-cell populations specific for Flu1 and Flu2 were observed (data 
not shown).
The  spectratyping  analyses  suggested  that  markedly  altered 
expansions of memory T cells could be driven by the presence of 
Arg in the C-terminal non-core epitope flanking region. To dissect 
this repertoire disparity in more detail, we employed an unbiased 
template-switch  anchored  RT–PCR  to  characterize  all  expressed 
TRB gene products from tetramer-sorted CD4 +  T-cell lines primed 
with  wild-type,  P10  or  P11  Arg-substituted  HA305 − 320  peptides 
(Flu1, Flu2 and Flu3, respectively). The flow cytometric gating strat-
egy used to sort these antigen-specific CD4 +  T-cell populations is 
shown in Figure 3a. As shown in Figure 3b–d, expansions of greater 
magnitude  were  observed  in  response  to  Flu3  (28.7%  of  CD3 +   
T cells) compared with either Flu1 or Flu2 (19.4% and 22.6% of 
CD3 +  T cells, respectively). The quantitative clonotypic composi-
tion of each tetramer-positive CD4 +  T-cell population is shown in 
Table 1. The antigen-specific repertoires were markedly oligoclonal 
and highly skewed in all cases, especially in the Flu3-specific CD4 +  
T-cell population (Table 1). Furthermore, despite the occurrence 
of common sequences in the Flu1-, Flu2- and Flu3-specific lines, 
distinct  clonotypes  emerged  and  often  predominated.  A  repeat 
experiment with the same donor demonstrated a strikingly similar 
clonotypic composition in response to Flu1, Flu2 and Flu3 peptides 
with no significant difference (Chi square 0.72; P = 0.70) between 
experiments  (data  not  shown).  Furthermore,  good  concordance 
was observed with respect to the TRBV profiles obtained by spec-
tratyping for Flu1-specific and Flu2-specific lines (Fig. 2). Thus,   
C-terminally modified peptides can induce biased clonotypic selec-
tion from a common starting pool.
These data show that repertoire composition is altered relative 
to wild type when basic tail peptides are used to stimulate memory 
CD4 +  T-cell responses (Figs 2 and 3, and Table 1). This biased selec-
tion process suggests that basic residues in the C-terminal tail might 
preferentially enhance recognition by certain clonotypes, presum-
ably as a function of TCR structure.
Improved TCR binding affinity to C-terminally modified peptides. 
The mechanism that drives enhanced recognition of C-terminally 
modified peptides and the associated repertoire skewing remains 
unclear,  although  there  is  some  evidence  that  length  modula-
tion of the C-terminal peptide-flanking region can directly affect 
T-cell recognition14,28,29. To provide an experimental explanation 
for this observation, we generated soluble αβ TCRs specific for 
the HA305 − 320 epitope presented by HLA-DR1 (F11 and HA-C6 
TCRs), or by either HLA-DR1 or HLA-DR4 (HA1.7 TCR). We also 
manufactured  soluble  versions  of  HLA-DRα1*0101/DRβ1*0101 
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Figure 1 | Screening of Flu1-specific CD4 +  T-cell clones with peptide 
libraries. (a) Representative data generated by screening clone HA-CA with 
22 flanking variant peptides using IFn-γ ELIspot assays to examine the effects 
of amino-acid substitutions at P10 or P11. Error bars shown are standard 
deviation from three separate experiments. (b) summary of screening data 
generated with three different Flu1-specific CD4 +  T-cell clones (HA-C6, 
HA-C5 and HA-CA). overall, the most favoured consensus alterations 
include basic residues at P10 and P11. (c) The Flu1-specific clone HA1.7 was 
stimulated with the indicated concentrations of the Flu1 peptide, or altered 
peptides with Arg at P10 (Flu2) or P11 (Flu3), in IFn-γ ELIspot assays.
PBMC
11.7% 1.1% 4% 2.1%
Flu1 29.2% 3.5% 2.1% 0.7%
Flu2
57.3% 5.6% 6.8% 7.7%
Overlay
TRBV28 usage TRBV25 usage TRBV6-2 usage TRBV30 usage
Figure 2 | Immunoscope profiles from CD4 +  T-cell lines expanded with 
Flu1 or Flu2 (Arg at P10). short-term T-cell lines were generated from 
peripheral blood stimulated with either Flu1 or Flu2. Antigen-specific 
CD4 +  cells were isolated on the basis of HLA-DR1/HA305 − 320 tetramer 
staining, and TCR repertoires were assessed by spectratyping. The 
profiles of pooled CDR3β lengths for four TRBV families are shown. In 
peripheral blood, the expected Gaussian distribution is observed. Altered 
profiles for the Flu1-specific and Flu2-specific populations indicate 
oligoclonal expansions. Differences in TRBV family usage are also 
apparent, suggesting that particular clonotypic expansions can be driven 
by a C-terminally modified peptide. A representative example from three 
independent experiments is shown. ARTICLE
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and  HLA-DRα1*0101/DRβ1*0401  bound  to  Flu1  (HA305 − 320), 
Flu2 and Flu3 peptides. Biophysical analysis, using SPR, revealed 
that the binding affinity of the HA1.7, F11 and HA-C6 TCRs was 
increased by ~1.4–1.8-fold with Arg substituted into the C-termi-
nus of the peptide-flanking region at P10 (PKYVKQNTLKLRT) 
and ~ > 2 fold with Arg at P11 (PKYVKQNTLKLAR) (Fig. 4; Sup-
plementary Fig. S2). These data provide the first demonstration that 
changes in the C-terminal flanking region of MHC-II epitopes can   
substantially enhance TCR binding affinity, and indicate a mecha-
nism through which peptide flanking residues could influence rep-
ertoire selection. Although these increases in TCR/pMHC binding 
affinity may appear small, we and others have previously reported 
that even minimal changes in affinity can have a substantial impact 
on T-cell activation25,30. Furthermore, these increases in affinity can 
enhance the avidity of tetramer binding by up to three orders of 
magnitude (D.K.C and A.G., unpublished observations).
Interestingly, the previously published ternary structure of the 
HA1.7  TCR  bound  to  HLA-DR1/HA305 − 320  (ref.  31)  revealed 
that that the TCR cannot make direct contacts with the short side 
chains of either Ala at P10 or Thr at P11 in the native Flu1 pep-
tide. Indeed, the closest proximity between the TCR and either P10 
or P11 is over 8 Å, which is beyond the limits for atomic contacts   
(Fig. 5a). However, substitution with Arg, which has a long basic 
side chain, at either P10 or P11 could close this gap and allow further 
interactions to form between the peptide and the TCR. To investi-
gate this possibility from a theoretical perspective, we modelled the 
Arg at P10 and Arg at P11 substitutions, using the original struc-
ture of the HA1.7 TCR bound to HLA-DR1/HA305 − 320 (ref. 31)   
(PDB Code 1FYT) as a guide. This analysis indicated that Arg at 
either P10 (Fig. 5b) or P11 (Fig. 5c) could form a salt bridge with 
Asp28 in the TCR β-chain. These extra bonds could enhance TCR- 
binding  affinity  to  pMHC-II,  and  explain  the  observed  differ-
ences in both T-cell activation and repertoire selection between 
the native Flu1 peptide and the basic tail peptides Flu2 and Flu3. 
Thus, the presence of an Arg in the C-terminal flanking region 
appears to enhance T-cell activation by increasing the affinity of the 
TCR/pMHC-II interaction by potentially generating new contacts 
between the TCR and peptide.
Discussion
MHC-II molecules present peptide epitopes that include flanking 
regions, that can extend beyond the MHC-II binding groove, to 
CD4 +  T cells. Structural studies have demonstrated that cognate 
TCRs primarily engage amino acids in the core nonamer region of 
the epitope situated within the MHC-II groove, although some con-
tacts can also be made with residues in the flanking regions31,32. 
Perhaps  surprisingly,  it  appears  that  these  flanking  residues  can 
influence  CD4 +   T-cell  recognition10,29.  Indeed,  we  have  shown 
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Figure 3 | Flow cytometric sorting of CD4 +  T-cell lines. short-term T-cell lines were generated from peripheral blood stimulated with the indicated 
peptides. Viable CD3 + CD4 +  cells that bound the HLA-DR1/HA305 − 320 tetramer were sorted by flow cytometry, and a molecular analysis of expressed 
TRB gene rearrangements was conducted as described in the methods. (a) Gating strategy used to identify viable CD3 + CD4 +  tetramer-positive events 
in: (b) line Flu1, (c) line Flu2 and (d) line Flu3.
Table 1 | Clonotypic composition of CD4 +  T cells expanded 
using different Flu antigens.
TRBV CDR3 TRBJ Freq. (%)
Clonotypes of CD4 +  T cells expanded using Flu1
6–51 CAssYsGGVGETQY 2–5 25.49
25–1 CAssDGTFTEAF 1–1 21.57
92 CAssmsPGPREsPLH 1–6 13.73
25–13 CAssDAGLGDYEQY 2–7 11.76
284 CAssPPGAGEGETQY 2–5 7.84
28 CAssLIAEEEGYGYT 1–2 3.92
28 CAssTTGsTDTQY 2–3 3.92
5–4 CAssLGLAGGGDTQY 2–3 1.96
28 CAsTPGTGDVQPQH 1–5 1.96
5–65 CAssPLsQGVRGYT 1–2 1.96
28 CAssRTGsTDTQY 2–3 1.96
4–1 CAssTDRGPYEQY 2–7 1.96
24–1 CATsDEsYGYT 1–2 1.96
Clonotypes of CD4 +  T cells expanded using Flu2
25–13 CAssDAGLGDYEQY 2–7 32.43
28 CAssRLRGPYEQY 2–7 27.03
6–5 CAssYDPsPTYEQY 2–7 16.22
6–51 CAssYsGGVGETQY 2–5 13.51
284 CAssPPGAGEGETQY 2–5 2.70
92 CAssmsPGPREsPLH 1–6 2.70
25–1 CAssDAGLGDYEQY 2–3 2.70
30 CAYTTsGAVTDTQY 2–3 2.70
Clonotypes of CD4 +  T cells expanded using Flu3
5–65 CAssPLsQGVRGYT 1–2 69.70
12–3/4 CAssEGFGAFQPQH 1–5 30.30
superscript numbers indicate identical clonotypes.ARTICLE     
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previously that non-bound C-terminal flanking residues can alter   
T-cell activation in an MHC allele-transcending fashion; these effects 
apply  to  T-cell  clones,  lines  and  polyclonal  populations  directly   
ex vivo11. However, the mechanism for this potentially important 
phenomenon,  and  the  means  by  which  it  could  influence  TCR 
selection and activation, is currently unknown. Several hypotheses 
have been put forward to explain how substitutions in the residues 
that flank the core of an antigenic peptide might influence T-cell 
responses. These include altered peptide binding to the restricting 
HLA element, effects on cellular uptake and antigen processing and; 
changes in pMHC-II conformation33.
To  explore  the  role  of  MHC-II  peptide-flanking  regions,  we 
screened hemaggluttinin-specific CD4 +  T-cell clones using families 
of peptides, each with a range of different amino-acid substitutions 
in the C-terminus flank at P10 or P11, and confirmed that basic 
residues were among the most favoured. The observation that sub-
stitution of either the P10 Ala or P11 Thr of the universal HA305 − 320 
epitope  with  an  Arg  residue  resulted  in  altered  recognition  by   
cognate CD4 +  T cells provided a good model system to examine 
the role of the C-terminal flanking region in more detail. In a pre-
vious study, we excluded the possibility that these ‘basic tail’ pep-
tides exhibit improved binding to the restricting MHC element in   
this system11. We therefore proceeded to examine whether such 
substitutions could influence binding to cognate TCRs. Using SPR, 
we found that the presence of an Arg at P10 or P11 in the C-terminal 
epitope  flanking  region  enhanced  TCR/pMHC-II  affinity.  This 
enhanced binding provided a molecular mechanism for the observed 
alterations in the immunogenicity of basic tail peptides. However, 
such improved binding affinity was also surprising, considering that 
the previously published ternary structure of the HA1.7 TCR bound 
to HLA-DR1/HA305 − 320 (ref. 31) revealed that the TCR does not 
make direct contacts with the short side chains of either Ala at P10 
or Thr at P11 in the native Flu1 peptide. Molecular modelling sug-
gested that substitution at P10 or P11 with Arg, which has a long 
basic side chain, could close this gap and allow further interactions 
to form between the peptide and the TCR. These extra bonds could 
enhance the binding affinity between the TCR and peptide, and could 
explain the differences in T-cell activation and repertoire selection 
between the native Flu1 peptide and the basic tail peptides Flu2 and 
Flu3. Thus, the introduction of a positively charged, longer amino-
acid side chain in the C-terminal flanking region could allow for the 
formation of new bonds between the TCR and peptide, although 
formal proof that such bonds exist awaits further structural char-
acterization. Regardless, the presence of an Arg in the C-terminal   
flanking  region  seemed  to  enhance  T-cell  activation  by  increas-
ing the affinity of TCR for pMHC-II. Intriguingly, when basic tail   
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Figure 4 | The impact of altered C-terminal peptide flanking residues on TCR/pMHC-II affinity. sPR was used to quantify equilibrium binding of the 
HA1.7, F11 and HA-C6 TCRs to native and altered Flu peptides complexed with HLA-DR1 and HLA-DR4.  Representative data from three independent 
experiments are shown. (a) HA1.7 TCR binding to HLA-DR4 complexed with Flu1 (PKYVKQnTLKLAT). (b) HA1.7 TCR binding to HLA-DR4 complexed with 
Flu2 (PKYVKQnTLKLRT). (c) HA1.7 TCR binding to HLA-DR4 complexed with Flu3 (PKYVKQnTLKLAR). (d) HA1.7 TCR binding to HLA-DR1 complexed 
with Flu1. (e) HA1.7 TCR binding to HLA-DR1 complexed with Flu2. (f) HA1.7 TCR binding to HLA-DR1 complexed with Flu3. (g) F11 TCR binding to HLA-
DR1 complexed with Flu1. (h) F11 TCR binding to HLA-DR1 complexed with Flu2. (i) F11 TCR binding to HLA-DR1 complexed with Flu3. (j) HA-C6 TCR 
binding to HLA-DR1 complexed with Flu1. (k) HA-C6 TCR binding to HLA-DR1 complexed with Flu2. (l) HA-C6 TCR binding to HLA-DR1 complexed with 
Flu3. These data show that modifications in the C-terminal flanking region of peptide antigens restricted by mHC-II can impinge directly on TCR binding, 
with changes at P11 having greater effects than changes at P10. substitution to arginine at P10 or P11 markedly increased TCR/pmHC-II binding affinity.ARTICLE
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peptides were used to stimulate memory T-cell responses, striking 
differences were observed in repertoire composition despite similar 
numerical expansions. This biased selection process suggests that 
basic residues in the C-terminal tail might preferentially enhance 
recognition by certain clonotypes, presumably as a function of TCR 
structure. Further studies are ongoing to explore the underlying 
basis for these differential effects.
In summary, we have shown that basic tail peptides can enhance 
TCR/pMHC-II  affinities  into  the  range  typically  observed  for 
TCR/pMHC-I interactions18. This exciting observation suggests 
that universal augmentation of pMHC-II antigens through par-
ticular C-terminal modifications may be a realistic option, with 
attendant implications for vaccination and other immune system 
interventions.
Methods
Peptides. Peptides were synthesized commercially to  > 80% purity (EMC 
Microcollections, Tubingen, Germany). The following peptides were used: the 
universal influenza epitope HA305 − 320 (Flu1), PKYVKQNTLKLAT; C-terminally 
modified variants with Arg at P10 or P11 (Flu2 = PKYVKQNTLKLRT, Flu3 = -
KYVKQNTLKLAR); and a peptide library synthesized with variant peptides con-
taining substitutions of the native amino acids in the C-terminal flanking region at 
P10 and P11. The substitutions in each library peptide were Gly, Arg, Lys, Glu, Ser, 
Asp, Leu, Val, Phe and Tyr, covering conservative, basic, acidic, aliphatic and bulky 
hydrophobic changes.
Cell culture. Epstein–Barr virus-immortalized B-cell lines (BCLs) were cultured 
in RPMI (Invitrogen) supplemented with 10% fetal calf serum (FCS; Invitrogen), 
2 mM glutamine, 100 µg ml − 1 streptomycin, 100 IU ml − 1 penicillin and 25 mM 
HEPES (Sigma) (RPMI–FCS medium). All T-cell lines and clones were cultured 
in RPMI supplemented with 7% human AB serum, 2 mM glutamine, 100 µg ml − 1 
streptomycin, 100 IU ml − 1 penicillin and 25 mM HEPES (RPMI–AB medium).
PBMCs were obtained from two HLA-DR1 +  donors by density gradient 
centrifugation of heparinized blood layered onto an equal volume of Lymphoprep 
(Axis-Shield). All human samples were used in accordance with UK guidelines. 
T-cell lines and clones were generated as described previously11,34. Antigen-spe-
cific T cells were cloned out either using HLA-DR1/HA305 − 320 tetramer staining 
and cell sorting, or by limiting dilution assays. Three clones specific for HLA-DR1/
HA305 − 320 (HA-C6, HA-C5 and HA-CA) were used to screen peptide variants; 
a further clone (F11) was used for biophysical work. Clonality was confirmed by 
sequencing TRA and TRB gene rearrangements; HLA restriction was confirmed by 
using peptide titrations in the presence of HLA-DR1 +  matched and mismatched 
BCLs, together with another clone (HA1.7) restricted by HLA-DR1 and HLA-DR4 
(ref. 35).
Screening T-cell clones. The frequency of specific IFN-γ producing T cells was 
measured by ELISpot assay as described previously10. Briefly, mouse anti-human 
IFN-γ antibody 1-DIK (Mabtech) was added to a polymer-backed 96-well filtra-
tion ELISpot plate (MAIP-S-4510; Millipore). Plates were washed thoroughly and 
blocked with 100 µl of 10% FCS. Duplicate wells were set up with 200 T cells and 
1,500 BCLs (HLA-DR1 homozygous) per well with 0.1–1 µg ml − 1 of peptide. The 
plate was incubated at 37 °C for 16–18 h, then developed according to standard pro-
tocols. Wells were considered positive if the number of spots was at least twice that 
observed in the control (no antigen) wells and  > 5 spots per well. T-cell prolifera-
tion was measured by incorporation of 3[H] thymidine (Amersham Life Science).
Spectratyping. PBMCs were isolated from healthy HLA-DR1 +  donors and short-
term lines specific for Flu1 and Flu2 were set up over a period of 8–10 days. Cells 
were then stained with PE-conjugated HLA-DR1/HA305 − 320 tetramer (2 µg ml − 1) 
for 24 min at 37 °C, followed by 2 µl αCD4-FITC (Miltenyi) for 20 min at 4 °C. 
Tetramer-labelled cells were then either enriched using anti-PE MACS beads 
(Miltenyi) according to the manufacturer’s instructions or isolated using a MoFlo 
cell sorter (BD Biosciences). Purity was assessed by flow cytometry. Typically, 
1–2×104 antigen-specific T cells were obtained. Both the tetramer-positive and  
tetramer-negative fractions were processed, together with negative controls com-
prising unstimulated PBMCs. Determination of TRBV gene usage and  
immunoscope analysis was performed as described previously36. Briefly, total RNA 
was extracted using the RNeasy mini-kit (Qiagen) according to the manufac-
turer’s specifications. cDNA was then prepared by RNA reverse-transcription 
with 0.5 µg µl − 1 oligo (dT)17 and 200 U of Superscript II reverse transcriptase 
(Invitrogen). An aliquot of the cDNA synthesis reaction was amplified with each of 
24 TRBV family-specific primers as previously described37, together with a TRBC 
primer and a minor groove binder TaqMan probe (Applied Biosystems). Real-time 
quantitative PCR was carried out using an ABI 7300 device (Applied Biosystems). 
Subsequently, 2 µl of each amplification reaction was used as template in run-off  
reactions with a nested fluorescent TRBC-specific primer. In these reactions, 
all PCR products were copied into fluorescently-labelled single-stranded DNA 
fragments, irrespective of their TRBJ gene usage or CDR3β sequence. These fluo-
rescent products were separated on an ABI-PRISM 3730 DNA analyzer (Applied 
Biosystems). The size and intensity of each band were analysed with Immunoscope 
software4,36. Fluorescence intensity was plotted in arbitrary units on the y axis, 
with the x axis corresponding to CDR3β length in amino acids.
TCR clonotyping. Cell lines specific for HLA-DR1/HA305 − 320 were stained first 
with 1 µl, diluted 1:40, LIVE/DEAD Fixable Violet Dead Cell Stain (Invitrogen/Life 
Technologies) for 15 min at room temperature in the dark, then with allophycocy-
anin-conjugated tetramer for 20 min at 37 °C. Subsequently, cells were stained for 
20 min at room temperature in the dark with the following monoclonal antibodies: 
3 µl αCD3-FITC and 2 µl αCD8-PECy7 (BD Pharmingen); and 0.2 µl αCD4-
PECy5.5, αCD14-Pacific Blue and αCD19-Pacific Blue (Caltag/Life Technologies). 
Tetramer-labelled CD3 + CD4 +  cells were sorted viably at  > 98% purity using a cus-
tomized 20-parameter FACSAria II flow cytometer (BD Biosciences) directly into 
1.5 ml microtubes containing 100 µl RNAlater (Applied Biosystems). Clonotypic 
analysis was then conducted using a template-switch anchored reverse-transcription   
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Figure 5 | Molecular modeling of Arg substitutions in the C-terminal 
flanking region of the native Flu1 peptide. (a) HA1.7 TCR (TCRα green, 
TCRβ blue cartoon) bound to HLA-DR1 (grey cartoon) complexed with 
Flu1 (PKYVKQnTLKLAT; core region red sticks, flanking regions blue 
sticks). The HA1.7 TCR β-chain is beyond the limits for atomic contacts 
with either P10 or P11 in the native structure. (b,c) modelling shows that a 
new interaction, possibly a salt bridge, could be formed between the HA1.7 
TCR β-chain residue Asp28 and Arg substituted at either position 10 (b) 
or 11 (c) of the HA peptide. This new interaction could explain the increase 
in affinity observed for cognate TCR binding to Flu2 and Flu3 compared 
with Flu 1.ARTICLE     
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PCR to amplify all expressed TRB gene products without bias using a template-
switch anchored reverse transcription–PCR with a 3′-TRB constant region primer 
(5′-GGCTCAAACAAGGAGACCT-3′), as described previously with minor 
modifications38,39. Amplicons were subcloned, sampled, sequenced and analysed 
as described previously39,40. The international ImMunoGeneTics nomenclature41 
is used to display all TCR sequence data.
Generation of expression plasmids. The HA1.7, F11 and HA-C6 TCRs were 
generated from the corresponding CD4 +  T-cell clones as described previously42. All 
sequences were confirmed by automated DNA sequencing (Lark Technologies). A 
disulphide-linked construct was used to produce the soluble domains (variable and 
constant) for both the TCRα and TCRβ chains43. The HLA-DRα*0101 chain, tagged 
with a biotinylation sequence, DRβ*0101 chain and DRβ*0401 chain were also 
cloned and used to produce the pMHC-II molecules18. All constructs were inserted 
into separate pGMT7 expression plasmids under the control of the T7 promoter.
Protein expression and purification. Competent Rosetta DE3 Escherichia coli 
cells were used to produce the HA1.7, F11 and HA-C6 TCRα and TCRβ chains, 
the HLA-DRα1*0101 chain, the DRβ1*0101 chain and the DRβ1*0401 chain 
in the form of inclusion bodies using 0.5 mM isopropyl-β-d-thiogalactoside to 
induce expression as described previously42. The HLA-DRα1*0101 chain, the 
DRβ1*0101 chain and the DRβ1*0401 chain were purified into 8 M urea buffer 
(8 M urea, 20 mM TRIS pH8.1, 0.5 mM EDTA, 30 mM DTT) by ion exchange using 
a Poros50HQ column (GE Healthcare) to remove bacterial impurities. For a 1-litre 
TCR refold, 30 mg of TCRα chain was incubated for 15 min at 37 °C with 10 mM 
dithiothreitol (DTT) and added to cold refold buffer (50 mM TRIS pH8.1, 2 mM 
EDTA, 2.5 M urea, 6 mM cysteamine hydrochloride and 4 mM cystamine).  
After 15 min, 30 mg of TCRβ chain, also incubated for 15 min at 37 °C with 10 mM 
DTT, was added. For a 1-litre pMHC-II refold, 2 mg of HLA-DRα1*0101 chain 
was mixed with 2 mg of either the HLA-DRβ1*0101 chain or the DRβ1*0401 
chain and 0.5 mg of peptide for 15 min at 37 °C with 10 mM DTT44. The following 
peptides (generated by Peptide Protein Research) were used in separate refolds: 
PKYVKQNTLKLAT, PKYVKQNTLKLRT and PKYVKQNTLKLAR (basic tail 
peptide-flanking region changes are denoted in bold). This mixture was then added 
dropwise to cold refold buffer (25% glycerol, 20 mM TRIS pH8.1, 1 mM EDTA, 
2 mM glutathione reduced, 0.2 mM glutathione oxidized). Refolds were incubated 
for 72 h at 4 °C. Dialysis was carried out against 10 mM TRIS pH 8.1 until the 
conductivity of the refolds was  < 2 mS cm − 1. The refolds were then filtered, ready 
for purification steps. Refolded proteins were purified initially by ion exchange 
using a Poros50HQ column (GE Healthcare) and then gel-filtered into BIAcore 
buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 3 mM EDTA and 0.05% (v/v) Sur-
factant P20) using a Superdex200HR column (GE Healthcare). Protein quality was 
analysed by Coomassie-stained SDS–PAGE. Biotinylated pMHC-II was prepared 
as described previously45.
Surface plasmon resonance analysis. Binding analysis was performed using a 
BIAcore 3000 and a BIAcore T100 (GE Healthcare) equipped with a CM5 sensor 
chip, as reported previously42,46. Between 200 and 400 response units of bioti-
nylated pMHC-II was immobilized on streptavidin, which was chemically linked 
to the chip surface; pMHC-II was injected at a slow-flow rate (10 µl min − 1) to 
ensure uniform distribution on the chip surface. The HA1.7, F11 and HA-C6 TCRs 
were purified and concentrated to ~100 µM on the day of SPR analysis to minimize 
TCR aggregation. For equilibrium analysis, eight serial dilutions were carefully 
prepared in triplicate for each sample and injected over the relevant sensor chip at 
a flow rate of 45 µl min − 1 at 25 °C. Results were analysed using BIAevaluation 3.1, 
Microsoft Excel and Origin 6.1. The equilibrium binding constant (KD) values were 
calculated using a nonlinear curve fit (y = (P1x)/(P2 + x)). 
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